1108 related articles for article (PubMed ID: 26258604)
21. [Ocular myasthenia gravis: diagnostic aspects and evolution].
de Entrambasaguas M; López-Bernabé R; López-Alemany M
Rev Neurol; 2007 Apr 1-15; 44(7):397-403. PubMed ID: 17420965
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic accuracy and clinical utility of bed side tests versus laboratory tests in the diagnosis of ocular myasthenia.
Sivakumar P; Tagare S; Kumar M
Indian J Ophthalmol; 2022 Apr; 70(4):1331-1337. PubMed ID: 35326049
[TBL] [Abstract][Full Text] [Related]
23. Clinical Characteristics of Patients With Double-Seronegative Myasthenia Gravis and Antibodies to Cortactin.
Cortés-Vicente E; Gallardo E; Martínez MÁ; Díaz-Manera J; Querol L; Rojas-García R; Illa I
JAMA Neurol; 2016 Sep; 73(9):1099-104. PubMed ID: 27379450
[TBL] [Abstract][Full Text] [Related]
24. Acetylcholine receptor antibody characteristics in myasthenia gravis. II. Patients with penicillamine-induced myasthenia or idiopathic myasthenia of recent onset.
Vincent A; Newsom-Davis J
Clin Exp Immunol; 1982 Aug; 49(2):266-72. PubMed ID: 7127905
[TBL] [Abstract][Full Text] [Related]
25. T cell recognition of muscle acetylcholine receptor in ocular myasthenia gravis.
Wang ZY; Diethelm-Okita B; Okita DK; Kaminski HJ; Howard JF; Conti-Fine BM
J Neuroimmunol; 2000 Aug; 108(1-2):29-39. PubMed ID: 10900334
[TBL] [Abstract][Full Text] [Related]
26. Acetylcholine receptor antibody characteristics in myasthenia gravis. I. Patients with generalized myasthenia or disease restricted to ocular muscles.
Vincent A; Newsom-Davis J
Clin Exp Immunol; 1982 Aug; 49(2):257-65. PubMed ID: 6813004
[TBL] [Abstract][Full Text] [Related]
27. Myasthenia gravis: antibodies to acetylcholine receptor in ocular myasthenia gravis.
Oda K; Ito Y
J Neurol; 1981; 225(4):251-8. PubMed ID: 6169804
[TBL] [Abstract][Full Text] [Related]
28. Remarkably increased resistin levels in anti-AChR antibody-positive myasthenia gravis.
Zhang DQ; Wang R; Li T; Li X; Qi Y; Wang J; Yang L
J Neuroimmunol; 2015 Jun; 283():7-10. PubMed ID: 26004149
[TBL] [Abstract][Full Text] [Related]
29. Clinical Characteristics Associated With Secondary Generalization in Patients With Ocular Myasthenia Gravis: A Systematic Review and Meta-analysis.
Fang CEH; Bokre D; Wong SH
Neurology; 2023 Oct; 101(16):e1594-e1605. PubMed ID: 37643888
[TBL] [Abstract][Full Text] [Related]
30. Evidence of underdiagnosis of myasthenia gravis in older people.
Vincent A; Clover L; Buckley C; Grimley Evans J; Rothwell PM;
J Neurol Neurosurg Psychiatry; 2003 Aug; 74(8):1105-8. PubMed ID: 12876244
[TBL] [Abstract][Full Text] [Related]
31. A retrospective study of acetylcholine receptor antibody positive ocular myasthenia in the West of Scotland.
Farrugia ME; Cleary M; Carmichael C
J Neurol Sci; 2017 Nov; 382():84-86. PubMed ID: 29111026
[TBL] [Abstract][Full Text] [Related]
32. Ocular presentation of myasthenia gravis: A natural history cohort.
Kamarajah SK; Sadalage G; Palmer J; Carley H; Maddison P; Sivaguru A
Muscle Nerve; 2018 Apr; 57(4):622-627. PubMed ID: 28881457
[TBL] [Abstract][Full Text] [Related]
33. Comparison of anti-acetylcholine receptor profiles between Chinese cases of adult- and juvenile-onset myasthenia gravis using cell-based assays.
Yan C; Zhao R; Song J; Feng X; Xi J; Luo S; Zhong H; Zhou S; Li W; Zhao C
J Neuroimmunol; 2020 Dec; 349():577403. PubMed ID: 32992216
[TBL] [Abstract][Full Text] [Related]
34. Clinical features and treatment status of antiacetylcholine receptor antibody-positive ocular myasthenia gravis.
Isshiki Y; Mimura O; Gomi F
Jpn J Ophthalmol; 2020 Nov; 64(6):628-634. PubMed ID: 32936398
[TBL] [Abstract][Full Text] [Related]
35. Acetylcholine receptor antibody positivity rate in ocular myasthenia gravis: a matter of age?
Monte G; Spagni G; Damato V; Iorio R; Marino M; Evoli A
J Neurol; 2021 May; 268(5):1803-1807. PubMed ID: 33387011
[TBL] [Abstract][Full Text] [Related]
36. Enzyme-linked immunosorbent assay for antibody against the nicotinic acetylcholine receptor in human myasthenia gravis.
Kawanami S; Tsuji R; Oda K
Ann Neurol; 1984 Feb; 15(2):195-200. PubMed ID: 6367620
[TBL] [Abstract][Full Text] [Related]
37. Pediatric Autoimmune Ocular Myasthenia Gravis: Evaluation of Presentation and Treatment Outcomes in a Large Cohort.
Fisher KS; Gill J; Todd HF; Yang MB; Lopez MA; Abid F; Lotze T; Shah VS
Pediatr Neurol; 2021 May; 118():12-19. PubMed ID: 33684630
[TBL] [Abstract][Full Text] [Related]
38. Ocular myasthenia gravis in a senior population: diagnosis, therapy, and prognosis.
Allen JA; Scala S; Jones HR
Muscle Nerve; 2010 Mar; 41(3):379-84. PubMed ID: 19918767
[TBL] [Abstract][Full Text] [Related]
39. [Prognosis of thymectomy in treatment of ocular myasthenia gravis and relevant influencing factors].
Deng Y; Zhang X
Zhonghua Yi Xue Za Zhi; 2009 Jul; 89(27):1922-5. PubMed ID: 19953918
[TBL] [Abstract][Full Text] [Related]
40. Incidence, Epidemiology, and Transformation of Ocular Myasthenia Gravis: A Population-Based Study.
Hendricks TM; Bhatti MT; Hodge DO; Chen JJ
Am J Ophthalmol; 2019 Sep; 205():99-105. PubMed ID: 31077669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
